Eli Lilly to Acquire Akouos for up to $610M

Eli Lilly. Lilly to acquire Akouos to discover and develop treatments for hearing loss. 2022. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-akouos-discover-and-develop-treatments-hearing (last accessed October 18, 2022 ).

U.S. Securities and Exchange Commission. Free writing prospectus updating amendment no. 1 to form s-1, registration statement of Prime Medicine, Inc. filed. 2022. https://www.sec.gov/Archives/edgar/data/1894562/000162828022026673/fwp-10192022.htm (last accessed October 20, 2022 ).

U.S. Securities and Exchange commission. Amendment No. 1 to Form S-1, Registration Statement of Prime Medicine, Inc. filed. 2022. https://www.sec.gov/Archives/edgar/data/1894562/000162828022026329/primemedicines-1launch.htm#icf292c7e02294e55b5a376dd97b1555c_25 (last accessed October 15, 2022 ).

Foust KD , Wang X , McGovern VL , et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol, 2010; 28:271–274.

Foust KD , Wang X , McGovern VL , et al. Retraction note: rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2022. DOI: 10.1038/s41587-022-01497-7.

Voyager Therapeutics. Voyager therapeutics announces Pfizer license of next-generation AAV capsid for rare neurologic disease target. 2022. https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-announces-pfizer-license-next-generation (last accessed October 14, 2022 ).

Alexion AstraZeneca Rare Disease . Alexion AstraZeneca rare disease to acquire LogicBio® therapeutics to accelerate growth in genomic medicine . 2022. https://media.alexion.com/news-releases/news-release-details/alexion-astrazeneca-rare-disease-acquire-logicbior-therapeutics (last accessed October 14, 2022 ).

bluebird bio. bluebird bio Receives FDA Accelerated approval for SKYSONA® gene therapy for early , active cerebral adrenoleukodystrophy (CALD). 2022. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-receives-fda-accelerated-approval-skysonar-gene (last accessed October 15, 2022 ).

Liu A . A $3M gene therapy: Bluebird bio breaks its own pricing record with FDA approval of Skysona . FiercePharma. 2022. https://www.fiercepharma.com/pharma/3m-gene-therapy-bluebird-breaks-own-record-fda-approval-skysona (last accessed October 15, 2022 ).

ArchiMed. ArchiMed invests in PlasmidFactory , a German gene and cell therapy specialist. 2022. https://www.archimed.group/ArchiMed%20invests%20in%20PlasmidFactory,%20a%20German%20gene%20and%20cell%20therapy%20specialist (last accessed October 14, 2022 ).